Sarepta Therapeutics (SRPT) AI Stock Analysis

• Market Cap: $1.74B
• Dividend Yield: N/A
• Average Volume (3M): 6.33M
• Price to Earnings (P/E): 19.6
• Beta (1Y): 0.86
• Revenue Growth: 59.15%
• EPS Growth: -1881.09%
• Country: US
• Employees: 1,372
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -4.60
• Shares Outstanding: 98,277,030
• 10 Day Avg. Volume: 8,108,641
• 30 Day Avg. Volume: 6,327,184
• PEG Ratio: -0.29
• Price to Book (P/B): 29.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.86
• Enterprise Value/Market Cap: 6.89
• Enterprise Value/Revenue: 1.65
• Enterprise Value/Gross Profit: 6.63
• Enterprise Value/Ebitda: 24.88
• 1Y Price Target: $42.71
• Price Target Upside: 134.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 26

• Rating: 53 Neutral
• Price Target: $17.50 ▼(-3.85%Downside)

Sarepta Therapeutics' overall stock score reflects a combination of strong revenue growth and strategic shareholder support, tempered by significant technical weakness and profitability challenges. Long-term growth prospects remain, but short-term headwinds from technicals and operational hurdles weigh on the stock's current valuation.

Positive Factors

Profitability prospects

Management believes that the company can be profitable based on the ambulatory opportunity alone.

Regulatory engagement

The FDA has proactively asked about the use of sirolimus, suggesting that Elevidys may not be completely removed from the market.

Negative Factors

Market penetration

The inability to drive market penetration in the non-ambulatory setting represents a massive blow to the ELEVIDYS franchise.

Regulatory risks

The FDA is evaluating the need for further regulatory action on ELEVIDYS after reports of patient deaths due to acute liver failure.

Safety concerns

The risk-benefit profile of ELEVIDYS is deteriorating following reports of fatality related to the drug.

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc. is a biotechnology company focused on the discovery and development of precision genetic medicines to treat rare diseases. The company is a leader in the research and development of RNA-based therapeutics, gene therapy, and other genetic medicine technologies. Its core products are primarily aimed at treating Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration and weakness. Sarepta's portfolio includes approved therapies, such as EXONDYS 51, VYONDYS 53, and AMONDYS 45, which are exon-skipping therapies addressing specific mutations in the DMD gene.

How the Company Makes Money

Sarepta Therapeutics generates revenue primarily through the sale of its approved exon-skipping therapies for Duchenne muscular dystrophy. The company earns money by commercializing its products in the U.S. and through strategic partnerships and licensing agreements for international markets. Additionally, Sarepta is involved in research and development collaborations with other pharmaceutical companies and academic institutions, which may provide milestone payments and royalties. The company's earnings are significantly influenced by the successful regulatory approval and market adoption of its therapies, as well as ongoing advancements in its pipeline of genetic medicine candidates.

Sarepta Therapeutics Financial Statement Overview

Summary

Sarepta Therapeutics demonstrates strong revenue growth and a stable asset base, but faces profitability and cash flow challenges. The company is investing heavily in growth, potentially at the expense of short-term profitability. Careful management of operating expenses and strategic financing will be crucial for sustaining growth and improving financial health.

Income Statement

Sarepta Therapeutics has shown consistent revenue growth, with a notable increase in total revenue from $540 million in 2020 to $2.23 billion in TTM (Trailing-Twelve-Months). The gross profit margin remains strong, yet the company is facing challenges at the operating level with negative EBIT and EBITDA margins, indicating profitability issues. Net profit margin is also negative, pointing towards high operating expenses and potential inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, reflecting prudent financial leverage but potential exposure to interest rate risks. The equity ratio is stable, suggesting a solid asset base, though return on equity is negative due to net losses. This indicates challenges in generating sufficient returns for shareholders despite asset growth.

Cash Flow

The cash flow statement reveals negative operating and free cash flows, highlighting potential liquidity concerns. The company's ability to convert operating cash flow into net income is weak, with significant cash outflows from operations. Despite negative free cash flow growth, financing activities provide some liquidity cushion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.23B	1.90B	1.24B	933.01M	701.89M	540.10M
Gross Profit	1.81B	1.58B	1.09B	793.02M	604.84M	476.72M
EBITDA	-117.73M	333.06M	-439.20M	-582.12M	-306.08M	-453.38M
Net Income	-248.39M	235.24M	-535.98M	-703.49M	-418.78M	-554.13M
Balance Sheet
Total Assets	3.47B	3.96B	3.26B	3.13B	3.15B	2.98B
Cash, Cash Equivalents and Short-Term Investments	522.76M	1.35B	1.68B	1.99B	2.12B	1.94B
Total Debt	1.34B	1.34B	1.40B	1.62B	1.14B	1.07B
Total Liabilities	2.32B	2.44B	2.41B	2.74B	2.22B	2.22B
Stockholders Equity	1.14B	1.53B	859.34M	384.95M	928.01M	761.76M
Cash Flow
Free Cash Flow	-687.55M	-342.74M	-588.34M	-356.17M	-481.66M	25.26M
Operating Cash Flow	-547.15M	-205.79M	-500.99M	-325.35M	-443.17M	107.47M
Investing Cash Flow	245.59M	755.56M	-165.80M	-1.05B	495.41M	-121.72M
Financing Cash Flow	115.14M	124.81M	125.00M	232.51M	561.57M	682.32M

Sarepta Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 18.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Negative. The current price of 18.2 is below the 20-day moving average (MA) of 26.89, below the 50-day MA of 38.26, and below the 200-day MA of 91.72, indicating a bearish trend. The MACD of -6.62 indicates Positive momentum. The RSI at 22.92 is Positive, neither overbought nor oversold. The STOCH value of 17.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRPT.

Sarepta Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKS	77 Outperform	$4.78B	13.81	25.71%	―	-12.31%	-17.53%
LEGN	56 Neutral	$6.68B	―	-20.00%	―	112.46%	54.33%
AXSM	54 Neutral	$5.07B	―	-282.16%	―	72.16%	9.65%
SRPT	53 Neutral	$1.74B	19.61	-23.61%	―	59.15%	-1881.09%
RVMD	52 Neutral	$6.87B	―	-36.68%	―	-100.00%	5.49%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
BPMC	50 Neutral	$8.30B	―	-47.71%	―	99.19%	48.43%

Sarepta Therapeutics Corporate Events

Sarepta Therapeutics Approves Amendments at Annual Meeting

On June 5, 2025, Sarepta Therapeutics held its annual meeting where stockholders approved amendments to the company’s equity and employee stock purchase plans, increasing the number of shares available under these plans. Additionally, stockholders elected new directors, approved executive compensation, and ratified KPMG as the independent auditor, indicating strong shareholder support for the company’s strategic initiatives and governance.

The most recent analyst rating on (SRPT) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.